Management Team
- Dr. Aiping H. Young, MD, PhD
President and Chief Executive Officer
- Dr. Yoon Lee, PhD
Vice President, Research - Elizabeth Williams, CA
Director of Finance and Administration (Acting CFO) - Peter Murray
Director, Clinical Development
Dr. Aiping H. Young, MD, PhD
President and Chief Executive Officer
Dr. Aiping Young has served as President and CEO as well as a board member of Lorus since October 2006. Prior to this, she held several progressive positions at Lorus (1999-2006), including Senior VP, Chief Technology Officer and Chief Operating Officer. In 1996, Dr. Young was cofounder, with Dr. Wright, of GeneSense Technologies Inc. and served as VP of R&D until its merger with Lorus in 1999. Dr. Young previously held the positions of Senior Scientist, Group Leader and Medical and Scientific Advisor for Pias Corporation in Japan. Dr. Young has published two books and numerous scientific papers in diverse bioscience areas (e.g. physiology, molecular biology, pharmacology and cell biology) and has co-authored several key patents that have come out of Lorus’ research activities. She holds a medical degree from Jiangxi Medical College in China (1979), and a Ph.D. in Pharmacology from Toyama Medical & Pharmaceutical University in Japan (1989). Dr. Young has been a Research Associate at the University of Manitoba and held the position of an Adjunct Scientist at the Manitoba Institute of Cell Biology in The Manitoba Cancer Treatment and Research Foundation in Winnipeg, Manitoba.
Dr. Yoon Lee, PhD
Vice President, Research
Dr. Lee is currently Vice President of Research. Dr. Lee has been with Lorus for ten years, most recently serving as the Director of Research. In these roles he has been responsible for overseeing research discovery and product development programs, including anticancer RNA-targeted therapeutics and small molecules. Dr. Lee received his Ph.D. degree in Molecular Biology and Genetics from the University of Guelph and completed a three-year post-doctoral training program at the University of Michigan. He joined Lorus in 1999 through the merger with GeneSense Technologies Inc., where he was a Research Scientist integrally involved in the development of GeneSense oligonucleotide therapeutics program. He has authored many scientific publications and numerous patents and conference proceedings.
Elizabeth Williams, CA
Director of Finance and Administration (Acting CFO)
Ms. Williams joined Lorus in 2004 as Corporate Controller and became Director of Finance in 2005. Prior to joining Lorus, Ms. Williams was Audit Manager for Ernst & Young LLP providing audit services to a large number of SEC traded companies and others. Ms. Williams, a graduate of Wilfrid Laurier University in 2000, received her designation as a Chartered Accountant in 2002. Since joining Lorus, she has taken on progressively increasing responsibilities in the financial management, planning and corporate governance of the corporation.
Peter Murray
Director, Clinical Development
Mr. Murray joined Lorus in 2002 as Director, Clinical Development, bringing more than 30 years of clinical development experience in biotechnology and pharmaceutical research including almost 20 years in Big Pharma. From a background in microbiology and biophysics, his former positions included Senior Clinical Scientist and head of Clinical Pharmaceutical Operations for Parke Davis Canada, Manager of International Clinical Research in Parke Davis Global Research, and Manager International Clinical Research in Pfizer Global Research and Development. Prior drug development experience spans multiple therapeutic areas including oncology and as clinical representative on New Product Development and New Business Development committees. Since joining Lorus he has been integrally involved in the clinical development planning and positioning of the Lorus product portfolio.